Search - IRCCS

A grant of €640,500 from the Ligue Contre le Cancer for Prof. BACHY’s Team: Towards a New Approach to CAR T Cells

In response to the 2024 call for proposals of the Ligue Contre le Cancer "Innovative cell therapies in oncology: new vectors, new targets", Prof. Emmanuel BACHY's team has obtained a grant of € 640,500 for the project "Functional improvement of CAR-T cells by Boolean and epigenetic approaches". This 3-year project is being carried out in collaboration with Prof. Olivier Hermine, Head of the Hematology Department at Necker Hospital and Director of Inserm Unit U1163 at the Imagine Institute in Paris, Prof. Michel Sadelain, Head of the Center for Cell Engineering at Memorial Sloan Kettering Cancer (MSKCC) in New York and Dr. Laurent Genestier, co-director of the Lymphoma Immunobiology team in Lyon (LIB) Inserm U1111-CNRS UMR 5308.

COMBOLA (GFM)

Etude multicentrique de phase I/II randomisée évaluant luspatercept seul ou en association avec l’ASE (Agents Stimulant l’Erythropoïèse) dans les Syndromes myélodysplasiques de faible risque non sidéroblastiques en échec ou non éligibles aux Agents Stimulants l’Erythropoïèse

See trial

Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study

Prof Pier Luigi Zinzani MD, Koji Izutsu MD, Neha Mehta-Shah MD, Stefan K Barta MD, Prof Kenji Ishitsuka MD, Raul Córdoba MD, Shigeru Kusumoto MD, Emmanuel Bachy MD, Kate Cwynarski PhD, Giuseppe Gritti MD, Anca Prica MD, Eric Jacobsen MD, Tatyana Feldman MD, Yann Guillermin MD, Daisuke Ennishi MD, Dok Hyun Yoon MD, Eva Domingo Domenech MD, Prof Jasmine Zain MD, Jie Wang MD, Prof Jin Seok Kim MD, ..., Steven M Horwitz MD

Accéder à l’article

FIRST_ALLO_MDS (AP-HP)

Greffe à partir d’un donneur familial en première intention pour les patients atteints de syndrome myélodysplasique : une étude de phase 2

See trial

TERN701-1012 (TERNS Ph.)

Essai clinique de phase 1 visant à évaluer la sécurité d’emploi, la tolérance, la pharmacocinétique et l’efficacité du TERN‐701 chez des participants atteints de leucémie myéloïde chronique

See trial

Trial temporarily suspended

UCART20x22_01 (CELLECTIS)

Étude de recherche et d’extension de dose en ouvert visant à évaluer la sécurité, l’expansion, la persistance et l’activité clinique de l’UCART20x22 chez des patients atteints de lymphome non hodgkinien à cellules B en rechute ou réfractaire (LNH-B)

See trial

Clinical research associate (CRA)

A clinical research associate (CRA) is a professional specialized in the management and coordination of clinical trials. Clinical trials are studies conducted to evaluate the effectiveness and safety of new treatments, drugs, medical devices or therapeutic interventions before they are placed on the market.

Discover

Biological sample management technician

The role of the biological sample management technician is to prepare samples (blood, tissues, etc.) from patients suffering from hematologic malignancies so that they can be sent and then analyzed by a reference laboratory chosen by the sponsor (centralized laboratory) . He has a transversal role by collaborating with CRAs and healthcare staff (doctors and nurses) on several clinical trials.

Discover

Study nurse (SN)

Pivotal in the care of patients in the department’s clinical trials, study nurses are the direct referents of patients. They administer treatments according to protocol prerequisites and are present at each visit.

Discover

Dr Maël Heiblig in the spotlight: oral participation at ASH 2024

Session: 615. Acute Myeloid Leukemias: Clinical and Epidemiology: Genetic Markers and Outcomes in AML

Accéder à l’article

Sector project manager

The sector project manager supervises clinical research studies in his/her sector of activity, optimizes the distribution of tasks, and collaborates with the clinical research manager to guarantee the smooth running of the trials.

Discover

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.

Touzeau C, Krishnan AY, Moreau P, Perrot A, Usmani SZ, Manier S, Cavo M, Martinez Chamorro C, Nooka AK, Martin TG, Karlin L, Leleu X, Bahlis NJ, Besemer B, Pei L, Stein S, Wang Lin SX, Trancucci D, Verona RI, Girgis S, Miao X, Uhlar CM, Chastain K, Garfall AL

Accéder à l’article